Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
12
SKYE Quote, Financials, Valuation and Earnings
Last price:
$2.47
Seasonality move
:
61.45%
Day range:
$2.39 - $2.68
52-week range:
$2.25 - $19.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
249.72x
P/B ratio:
0.98x
Volume:
175.8K
Avg. volume:
199.9K
1-year change:
-3.53%
Market cap:
$74.6M
Revenue:
--
EPS (TTM):
-$0.84
Analysts' Opinion
-
Consensus RatingSkye Bioscience has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Skye Bioscience has an estimated upside of 631.71% from its current price of $2.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.46.
Fair Value
-
According to the consensus of 0 analysts, Skye Bioscience has 631.71% upside to fair value with a price target of -- per share.
SKYE vs. S&P 500
-
Over the past 5 trading days, Skye Bioscience has underperformed the S&P 500 by -14.56% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Skye Bioscience does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Skye Bioscience revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Skye Bioscience reported revenues of --.
Earnings Growth
-
Skye Bioscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Skye Bioscience reported earnings per share of -$0.10.
Enterprise value:
7.2M
EV / Invested capital:
--
Price / LTM sales:
249.72x
EV / EBIT:
--
EV / Revenue:
24.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.32x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$11.5M | -$12.7M | -$28.2M | -$3.5M | -$9.5M | |
| EBITDA | -$11.2M | -$42.4M | -$19.5M | -$24.6M | -$3.5M | |
| Diluted EPS | -$6.58 | -$9.28 | -$0.84 | -$3.17 | -$0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.3M | $11.4M | $2.7M | $15.3M | $79.8M | |
| Total Assets | $4.3M | $11.7M | $2.9M | $15.6M | $81.5M | |
| Current Liabilities | $1.2M | $1.5M | $6.1M | $13.7M | $5.6M | |
| Total Liabilities | $2.5M | $3.4M | $6.2M | $13.9M | $5.7M | |
| Total Equity | $1.9M | $8.3M | -$3.3M | $1.7M | $75.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.8M | -$15M | -$20.9M | -$4.1M | -$5.3M | |
| Cash From Investing | -$506.1K | $12.3M | -$343K | $1.1M | -$1.4M | |
| Cash From Financing | -$326.7K | $16.5M | $83.5M | $16.6M | -- | |
| Free Cash Flow | -$9.9M | -$15M | -$22.5M | -$4.1M | -$6.8M | |
SKYE
Sector
Market Cap
$74.6M
$45.9M
Price % of 52-Week High
12.67%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-3.53%
-32.15%
Beta (5-Year)
1.719
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.77
200-day SMA
Sell
Level
$7.61
Bollinger Bands (100)
Sell
Level
3.59 - 5.67
Chaikin Money Flow
Sell
Level
-76.2M
20-day SMA
Sell
Level
$3.38
Relative Strength Index (RSI14)
Sell
Level
25.12
ADX Line
Sell
Level
35.09
Williams %R
Buy
Level
-95.4128
50-day SMA
Sell
Level
$4.31
MACD (12, 26)
Sell
Level
-0.51
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Sell
Level
-36.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Stock Forecast FAQ
In the current month, SKYE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SKYE average analyst price target in the past 3 months is --.
-
Where Will Skye Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Skye Bioscience share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Skye Bioscience?
Analysts are divided on their view about Skye Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Skye Bioscience is a Sell and believe this share price will drop from its current level to --.
-
What Is Skye Bioscience's Price Target?
The price target for Skye Bioscience over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SKYE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Skye Bioscience is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SKYE?
You can purchase shares of Skye Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Skye Bioscience shares.
-
What Is The Skye Bioscience Share Price Today?
Skye Bioscience was last trading at $2.47 per share. This represents the most recent stock quote for Skye Bioscience. Yesterday, Skye Bioscience closed at $2.46 per share.
-
How To Buy Skye Bioscience Stock Online?
In order to purchase Skye Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
